leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 00:47:16 - browse：66441

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： New documents shed light on MD Anderson Cancer Institute feud

WSS

How artificial intelligence is being used to detect, treat cancer

7 of the most gruesome medical devices in history

He's a Nobel laureate. Critics say he was misleading on Covid

Organ transplantation is at a crossroads. Major reform is needed

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Alkermes shareholders re

New documents shed light on MD Anderson Cancer Institute feud

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Review: 'Barbie' will hit you like a shot in the heart

Sports medicine is finally prioritizing gender equality

Why an extreme heat and wildfire smoke combination can be so dangerous

Tori Bowie and the unacceptable rates of Black maternal death

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Medicare details structure of new drug price negotiation program

With competition flaring, obesity drug hits goal in liver disease study

entertainment

Caitlin Bernard's story shows physicians can't shy from advocacy

AbbVie dramatically boosts its spending on lobbying

Alabama frozen embryo ruling has major implications for IVF clinics

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Elizabeth Warren probes abortion access

Dario to buy mental health app maker Twill in cash and stock deal

focus

Wikipedia

entertainment

hotspot